|My end of year review of GERN|
INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too.
GERN (market cap is $0.186B was $0.594B)
Geron is a leading edge biotech company developing treatments for cancer through the management of telomeres, the molecules that manage cell growth and death. Treatments are in clinical trials, which means they are beyond simple lab tests, but it also means they have yet to apply for or achieve FDA approval. A classic risk/reward trade because the risks of getting approval for innovative treatments is difficult, and the rewards are great because of a great unmet need with very little competition.
They are continuing through clinical trials, but have not produced results that have enthused the investing community. The company has also been shedding intellectual assets for years (see AST), and has had to rely on partner companies.
I’ll continue to hold. I’ve sold shares to buy into other opportunities, but want to hold onto a core, just in case.
DISCLOSURE LTBH since 1999 and continuing to hold. I might consider buying more, but will probably wait for substantial, quantitative results are made public - which would spark a spike that might price me out of the sale. Stay tuned.
(I've also collected links to the other discussion boards and my other stocks over on my blog trimbathcreative.wordpress.com